Pitfalls to Avoid for a Strong Oncology Market Entry: Current and Future Risk Levels for Product, Market, Physician, Patient, Payer, Internal and Regulatory Pitfalls

STUDY OVERVIEW

For a new oncology product to successfully enter the marketplace, organizations have to be vigilant of the many pitfalls that are part of the launch landscape. This research document highlights launch leaders' perspective on the current and future risk levels of potential pitfalls for critical oncology launch factors such as product and market makeup, physicians, patients, payers, internal issues and regulatory. Pharmaceutical product launch leaders can use this study to better understand the potential pitfalls and stumbling blocks that they'll have to navigate as part of a new oncology product entering the market.

KEY TOPICS

• Pitfalls and Stumbling Blocks
• Lessons Learned, Best Practices and Future Changes

• Estimate for the risk level of product shaping pitfalls that can derail a new oncology product coming into a crowded market
• Estimate for the risk level of market shaping pitfalls that can derail a new oncology product coming into a crowded market
• Estimate for the risk level of physician pitfalls that can derail a new oncology product coming into a crowded market
• Estimate for the risk level of patient pitfalls that can derail a new oncology product coming into a crowded market
• Estimate for the risk level of payer pitfalls that can derail a new oncology product coming into a crowded market
• Estimate for the risk level of internal failure points that can derail a new oncology product coming into a crowded market
• Estimate for the risk level of regulatory pitfalls that can derail a new oncology product coming into a crowded market

• Physician-Level Pitfalls: Key Oncology stumbling blocks reside with thought leaders and critical specialists critics. However, health care access is seen as most likely risk to increase during the next two to three years.

• Payer Risk Factors: Payer risk factors are in high alert across multiple therapeutic areas and across many fronts: Pricing, Priorities, Health Outcomes and Managed Markets. Looking ahead, over half of the Oncology participants see risk intensity continuing to rise.

The research employed a data gathering approach that gleaned quantitative data from 44 executives and managers from 38 leading companies in pharmaceutical, biotechnology and medical device industries.

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.